NL301292I2 - Iptacopan of een farmaceutisch aanvaardbaar zout daarvan - Google Patents

Iptacopan of een farmaceutisch aanvaardbaar zout daarvan

Info

Publication number: NL301292I2
Authority: NL; Netherlands
Prior art keywords: iptacopan; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2013-07-15

Application number

NL301292C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-15

Filing date

2024-10-07

Publication date

2024-10-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51230246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301292(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2024-10-07 Application filed by Novartis Ag filed Critical Novartis Ag

2024-10-30 Publication of NL301292I2 publication Critical patent/NL301292I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL301292C 2013-07-15 2024-10-07 Iptacopan of een farmaceutisch aanvaardbaar zout daarvan NL301292I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361846355P	2013-07-15	2013-07-15
US201461977028P	2014-04-08	2014-04-08
PCT/US2014/046515 WO2015009616A1 (en)	2013-07-15	2014-07-14	Piperidinyl indole derivatives and their use as complement factor b inhibitors

Publications (1)

Publication Number	Publication Date
NL301292I2 true NL301292I2 (nl)	2024-10-30

Family

ID=51230246

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301292C NL301292I2 (nl)	2013-07-15	2024-10-07	Iptacopan of een farmaceutisch aanvaardbaar zout daarvan

Country Status (40)

Country	Link
US (2)	US9682968B2 (nl)
EP (2)	EP3022192B1 (nl)
JP (1)	JP6378761B2 (nl)
KR (1)	KR102242742B1 (nl)
CN (1)	CN105579444B (nl)
AP (1)	AP2016008992A0 (nl)
AU (1)	AU2014290298B2 (nl)
BR (1)	BR112016000909B1 (nl)
CA (1)	CA2917839C (nl)
CL (1)	CL2016000060A1 (nl)
CU (1)	CU24397B1 (nl)
CY (2)	CY1119767T1 (nl)
DK (1)	DK3022192T3 (nl)
EA (1)	EA031030B1 (nl)
ES (1)	ES2655855T4 (nl)
FI (1)	FIC20240032I1 (nl)
FR (1)	FR24C1036I2 (nl)
GT (1)	GT201600007A (nl)
HR (1)	HRP20172000T1 (nl)
HU (2)	HUE037510T2 (nl)
IL (2)	IL243540B (nl)
JO (1)	JO3425B1 (nl)
LT (2)	LT3022192T (nl)
MX (1)	MX351291B (nl)
MY (2)	MY196427A (nl)
NL (1)	NL301292I2 (nl)
NO (1)	NO2024042I1 (nl)
PE (1)	PE20161066A1 (nl)
PH (1)	PH12016500072B1 (nl)
PL (1)	PL3022192T3 (nl)
PT (1)	PT3022192T (nl)
RS (1)	RS56721B1 (nl)
SG (1)	SG11201600086PA (nl)
SI (1)	SI3022192T1 (nl)
SV (1)	SV2016005137A (nl)
TN (1)	TN2016000017A1 (nl)
TW (1)	TWI641600B (nl)
UA (1)	UA117371C2 (nl)
UY (1)	UY35663A (nl)
WO (1)	WO2015009616A1 (nl)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3425B1 (ar)	2013-07-15	2019-10-20	Novartis Ag	مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AR106018A1 (es)	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340982B1 (en)	2015-08-26	2021-12-15	Achillion Pharmaceuticals, Inc.	Compounds for treatment of immune and inflammatory disorders
CN116554168B (zh)	2016-06-21	2025-09-23	X4制药有限公司	Cxcr4抑制剂及其用途
CA3027500A1 (en) *	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Cxcr4 inhibitors and uses thereof
JP7057290B2 (ja)	2016-06-27	2022-04-19	アキリオンファーマシューティカルズ，インコーポレーテッド	医学的障害を治療するためのキナゾリン及びインドール化合物
CN107641121B (zh) *	2016-07-20	2021-02-19	上海高驰资产管理有限公司	一种荧光探针及其制备方法和用途
WO2018160889A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceuticals, Inc.	Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
MA46990B1 (fr)	2017-08-24	2024-03-29	Novo Nordisk As	Compositions glp-1 et ses utilisations
BR112020003737A2 (pt)	2017-08-31	2020-09-01	Novartis Ag	usos de derivados de piperidinil-indol
JP2021530505A (ja)	2018-07-16	2021-11-11	ノバルティスアーゲー	フェニルピペリジニルインドール誘導体を調製する化学的プロセス
US20230022157A1 (en)	2018-08-20	2023-01-26	Achillion Pharmaceuticals, Inc.	Pharmaceutical compounds for the treatment of complement factor d medical disorders
MX2021002640A (es)	2018-09-06	2021-07-16	Achillion Pharmaceuticals Inc	Formas morficas de los inhibidores del factor d del complemento.
WO2020051532A2 (en)	2018-09-06	2020-03-12	Achillion Pharmaceuticals, Inc.	Macrocyclic compounds for the treatment of medical disorders
AU2019346464A1 (en)	2018-09-25	2021-04-08	Achillion Pharmaceuticals, Inc.	Morphic forms of complement factor D inhibitors
AU2020207638B2 (en)	2019-01-11	2023-04-13	Novartis Ag	LTA4H inhibitors for the treatment of Hidradenitis Suppurativa
WO2020144605A1 (en)	2019-01-11	2020-07-16	Novartis Ag	Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
TW202535454A (zh)	2020-02-18	2025-09-16	丹麥商諾佛儂迪克股份有限公司	醫藥配方
JP2023515073A (ja)	2020-02-20	2023-04-12	アキリオンファーマシューティカルズ，インコーポレーテッド	補体因子ｄ媒介障害の処置用のヘテロアリール化合物
CN120172955A (zh)	2020-05-18	2025-06-20	诺华股份有限公司	Lnp023的结晶形式
US11951101B2 (en)	2020-07-16	2024-04-09	Novartis Ag	Methods of using factor B inhibitors
EP4181922A1 (en)	2020-07-16	2023-05-24	Novartis AG	Methods of using factor b inhibitors
WO2022028507A1 (zh) *	2020-08-07	2022-02-10	上海美悦生物科技发展有限公司	一种杂环类化合物、其制备方法及用途
AU2021323300B2 (en) *	2020-08-07	2025-12-18	Shanghai Meiyue Biotech Development Co., Ltd.	Complement factor B inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
CA3193488A1 (en)	2020-09-23	2022-03-31	Jason Allan Wiles	Pharmaceutical compounds for the treatment of complement mediated disorders
EP4273137A4 (en) *	2020-12-30	2025-01-01	S-Infinity Pharmaceuticals Co.,Ltd	SERIES OF PIPERIDINE-SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE
CN116438170B (zh) *	2020-12-30	2024-12-13	江苏恒瑞医药股份有限公司	含氮桥杂环化合物、其制备方法及其在医药上的应用
EP4277982A1 (en) *	2021-01-14	2023-11-22	Alexion Pharmaceuticals, Inc.	Macrocycle complement factor b inhibitors
EP4324828A4 (en) *	2021-04-16	2025-06-25	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID COMPOUNDS
CN117479937A (zh)	2021-05-07	2024-01-30	诺华股份有限公司	用于治疗非典型溶血性尿毒综合征的伊普可泮
US20240287034A1 (en) *	2021-06-03	2024-08-29	Chinook Therapeutics, Inc.	Substituted indole compounds and methods of use thereof
WO2022264101A1 (en)	2021-06-18	2022-12-22	Novartis Ag	Method of treating an autoimmune hematological disorder
US20240360103A1 (en) *	2021-06-30	2024-10-31	Apellis Pharmaceuticals, Inc.	Complement inhibition
KR20240049561A (ko) *	2021-08-18	2024-04-16	시젱 하이스코 파마수티칼 씨오., 엘티디.	벤즈아제핀 방향족 고리 유도체 및 이의 의약에서의 응용
JP2024530344A (ja) *	2021-09-07	2024-08-16	ノバルティスアーゲー	加齢黄斑変性の処置のためのｂ因子阻害剤の使用
MX2024004921A (es) *	2021-10-27	2024-06-19	Hansoh Bio Llc	Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
CR20240300A (es)	2022-01-24	2024-08-23	Novartis Ag	Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos.
EP4471021A4 (en) *	2022-01-26	2025-04-30	Shanghai Meiyue Biotech Development Co., Ltd.	Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
TW202342048A (zh)	2022-02-28	2023-11-01	瑞士商諾華公司	使用ｌｏｕ０６４治療化膿性汗腺炎之方法
US20250195492A1 (en)	2022-03-04	2025-06-19	Novartis Ag	Use of iptacopan for the treatment of lupus nephritis
CN119137099A (zh)	2022-04-01	2024-12-13	诺华股份有限公司	补体因子b抑制剂及其用途
CN119698414A (zh) *	2022-06-20	2025-03-25	深圳信立泰药业股份有限公司	一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2023246870A1 (zh) *	2022-06-23	2023-12-28	上海济煜医药科技有限公司	吲哚化合物的制备、应用及用途
AU2023299821A1 (en) *	2022-06-30	2025-02-13	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Pharmaceutically acceptable salt and crystal form of nitrogen-containing bridge heterocyclic derivative, and method for preparing same
CN119768397A (zh) *	2022-08-29	2025-04-04	深圳市康哲生物科技有限公司	一系列含氮桥杂环化合物及其制备方法
WO2024049977A1 (en) *	2022-08-31	2024-03-07	Chinook Therapeutics, Inc.	Substituted indole compounds and methods of use thereof
AU2023339335A1 (en)	2022-09-10	2025-04-03	Hansoh Bio Llc	2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
KR20250103768A (ko)	2022-11-11	2025-07-07	상하이 이셩 바이오파마슈티컬 컴퍼니 리미티드	피리딘 치환 벤조산계 화합물, 이의 약학 조성물 및 용도
WO2024104292A1 (en) *	2022-11-14	2024-05-23	Novartis Pharma Ag	Solid forms of complement factor b inhibitors
WO2024114677A1 (zh) *	2022-11-29	2024-06-06	上海济煜医药科技有限公司	苯并螺环吲哚化合物的制备、应用及用途
WO2024141011A1 (zh) *	2022-12-31	2024-07-04	深圳晶泰科技有限公司	补体因子b抑制剂及其药物组合物和应用
WO2024148274A1 (en) *	2023-01-05	2024-07-11	Apellis Pharmaceuticals, Inc.	Complement inhibition
TW202434240A (zh) *	2023-02-22	2024-09-01	大陸商西藏海思科製藥有限公司	苯並氮雜芳環衍生物的藥物組合物及其在醫藥上的應用
CN120676943A (zh)	2023-02-23	2025-09-19	诺华股份有限公司	使用因子b抑制剂的方法
WO2024193575A1 (zh) *	2023-03-21	2024-09-26	上海美悦生物科技发展有限公司	螺环类化合物及其药物组合物、制备方法和用途
WO2024222852A1 (zh)	2023-04-27	2024-10-31	上海翰森生物医药科技有限公司	一种哌啶基吲哚化合物的盐及其制备方法
WO2025008451A1 (en)	2023-07-04	2025-01-09	Sitala Bio Ltd	2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
WO2025008453A1 (en)	2023-07-04	2025-01-09	Sitala Bio Ltd	2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors
WO2025008517A1 (en)	2023-07-06	2025-01-09	Sitala Bio Ltd	Indole derivatives with factor b inhibitory activity
WO2025008516A2 (en)	2023-07-06	2025-01-09	Sitala Bio Ltd	Novel compounds
CN119371402A (zh) *	2023-07-26	2025-01-28	上海美悦生物科技发展有限公司	螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
WO2025046421A1 (en)	2023-08-25	2025-03-06	Novartis Ag	Methods of using factor b inhibitors
TW202515541A (zh)	2023-09-29	2025-04-16	瑞士商諾華公司	補體因子ｂ抑制劑及其用途
WO2025083621A1 (en)	2023-10-20	2025-04-24	Novartis Ag	Treatment of hidradenitis suppurativa using anti-baff-r antibodies
TW202535375A (zh) *	2023-12-05	2025-09-16	大陸商西藏海思科製藥有限公司	苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途
WO2025148628A1 (zh) *	2024-01-10	2025-07-17	河北以岭医药研究院有限公司	哌啶基吲哚衍生物及其制备方法和应用
WO2025172535A1 (en)	2024-02-15	2025-08-21	Sitala Bio Ltd	Indole and benzimidazole compounds as factor b inhibitors
TW202533829A (zh)	2024-02-16	2025-09-01	瑞士商諾華公司	用於治療anca相關性血管炎的因子b抑制劑
WO2025185734A1 (zh) *	2024-03-08	2025-09-12	江苏豪森药业集团有限公司	一种多元螺环化合物的盐及其晶型、其制备方法和医药用途
WO2025237237A1 (en) *	2024-05-11	2025-11-20	Alebund Pharmaceuticals (Hong Kong) Limited	Complement factor b inhibitors
WO2025252133A1 (zh) *	2024-06-07	2025-12-11	润尔眼科药物（广州）有限公司	一种含吲哚基团的化合物及其用途
WO2025256647A1 (zh) *	2024-06-14	2025-12-18	润尔眼科药物（广州）有限公司	化合物及其医药用途
WO2026002007A1 (zh) *	2024-06-25	2026-01-02	珠海联邦制药股份有限公司	补体因子b抑制剂及其药物组合物和应用
WO2026003809A1 (en)	2024-06-29	2026-01-02	Assia Chemical Industries Ltd.	Solid state forms of iptacopan hydrochloride
WO2026008074A1 (zh) *	2024-07-05	2026-01-08	南京正大天晴制药有限公司	补体因子b抑制剂的晶型、其制备方法及用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR030357A1 (es)	2000-08-18	2003-08-20	Lundbeck & Co As H	Derivados 4 -, 5 -, 6 - y 7-indol
DE10217006A1 (de) *	2002-04-16	2003-11-06	Merck Patent Gmbh	Substituierte Indole
DE10237723A1 (de) *	2002-08-17	2004-07-08	Aventis Pharma Deutschland Gmbh	Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
RS20050430A (sr)	2002-12-19	2007-08-03	Pfizer Inc.,	Jedinjenja 2-(1h-indazol-6-ilamino)- benzamida kao inhibitori protein kinaza, korisni u tretmanu oftalmoloških bolesti
EP1631260A2 (en)	2003-02-28	2006-03-08	Transform Pharmaceuticals, Inc.	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CN1812978A (zh)	2003-04-30	2006-08-02	药物研发有限责任公司	作为蛋白酪氨酸磷酸酶－1b抑制剂的苯基取代羧酸
AU2005307818A1 (en)	2004-11-18	2006-05-26	The Institutes For Pharmaceutical Discovery, Llc	Heterocyclylbiphenyl derivates as protein Tyrosine phosphatase inhibitors
EP1851203A2 (en)	2005-02-08	2007-11-07	Merck & Co., Inc.	Inhibitors of checkpoint kinases
EP2205085A1 (en)	2007-09-25	2010-07-14	Merck Sharp & Dohme Corp.	2-aryl or heteroaryl indole derivatives
US20100331298A1 (en)	2007-12-10	2010-12-30	Cytopathfinder, Inc.	Carboxamide Compounds and Their Use
AR070398A1 (es)	2008-02-22	2010-03-31	Gruenenthal Chemie	Derivados sustituidos de indol
JO3265B1 (ar)	2008-12-09	2018-09-16	Novartis Ag	مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
ES2759751T3 (es)	2009-07-14	2020-05-12	Nerviano Medical Sciences Srl	3-oxo-2,3-dihidro-1H-isoindol-4-carboxamidas
AU2010347233B2 (en)	2010-03-01	2015-06-18	Oncternal Therapeutics, Inc.	Compounds for treatment of cancer
WO2012068589A2 (en)	2010-11-19	2012-05-24	Constellation Pharmaceuticals	Modulators of methyl modifying enzymes, compositions and uses thereof
BR112013017316A2 (pt) *	2011-01-04	2019-09-24	Novartis Ag	compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
UY34781A (es) *	2012-05-04	2013-12-31	Novartis Ag	Moduladores de la via del complemento y usos de los mismos
WO2013192345A1 (en) *	2012-06-20	2013-12-27	Novartis Ag	Complement pathway modulators and uses thereof
JO3425B1 (ar)	2013-07-15	2019-10-20	Novartis Ag	مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b

2014
- 2014-07-13 JO JOP/2014/0224A patent/JO3425B1/ar active
- 2014-07-14 PL PL14744744T patent/PL3022192T3/pl unknown
- 2014-07-14 EP EP14744744.5A patent/EP3022192B1/en active Active
- 2014-07-14 AP AP2016008992A patent/AP2016008992A0/xx unknown
- 2014-07-14 MY MYPI2020004691A patent/MY196427A/en unknown
- 2014-07-14 EP EP17191470.8A patent/EP3299365A1/en not_active Withdrawn
- 2014-07-14 EA EA201690223A patent/EA031030B1/ru not_active IP Right Cessation
- 2014-07-14 DK DK14744744.5T patent/DK3022192T3/en active
- 2014-07-14 KR KR1020167003321A patent/KR102242742B1/ko active Active
- 2014-07-14 CN CN201480050471.1A patent/CN105579444B/zh active Active
- 2014-07-14 PT PT147447445T patent/PT3022192T/pt unknown
- 2014-07-14 SI SI201430522T patent/SI3022192T1/en unknown
- 2014-07-14 JP JP2016527011A patent/JP6378761B2/ja active Active
- 2014-07-14 HR HRP20172000TT patent/HRP20172000T1/hr unknown
- 2014-07-14 SG SG11201600086PA patent/SG11201600086PA/en unknown
- 2014-07-14 ES ES14744744T patent/ES2655855T4/es active Active
- 2014-07-14 CA CA2917839A patent/CA2917839C/en active Active
- 2014-07-14 TW TW103124190A patent/TWI641600B/zh active
- 2014-07-14 CU CU2016000006A patent/CU24397B1/es unknown
- 2014-07-14 HU HUE14744744A patent/HUE037510T2/hu unknown
- 2014-07-14 LT LTEP14744744.5T patent/LT3022192T/lt unknown
- 2014-07-14 AU AU2014290298A patent/AU2014290298B2/en active Active
- 2014-07-14 RS RS20171318A patent/RS56721B1/sr unknown
- 2014-07-14 UA UAA201600266A patent/UA117371C2/uk unknown
- 2014-07-14 US US14/904,694 patent/US9682968B2/en active Active
- 2014-07-14 WO PCT/US2014/046515 patent/WO2015009616A1/en not_active Ceased
- 2014-07-14 BR BR112016000909-6A patent/BR112016000909B1/pt active IP Right Grant
- 2014-07-14 TN TN2016000017A patent/TN2016000017A1/en unknown
- 2014-07-14 PE PE2016000651A patent/PE20161066A1/es active IP Right Grant
- 2014-07-14 MX MX2016000662A patent/MX351291B/es active IP Right Grant
- 2014-07-14 MY MYPI2016700023A patent/MY187454A/en unknown
- 2014-07-15 UY UY35663A patent/UY35663A/es active IP Right Grant
2016
- 2016-01-10 IL IL243540A patent/IL243540B/en active IP Right Grant
- 2016-01-11 PH PH12016500072A patent/PH12016500072B1/en unknown
- 2016-01-12 CL CL2016000060A patent/CL2016000060A1/es unknown
- 2016-01-14 SV SV2016005137A patent/SV2016005137A/es unknown
- 2016-01-14 GT GT201600007A patent/GT201600007A/es unknown
2017
- 2017-06-19 US US15/626,981 patent/US10093663B2/en active Active
2018
- 2018-01-08 CY CY20181100019T patent/CY1119767T1/el unknown
2019
- 2019-08-11 IL IL268623A patent/IL268623B/en active IP Right Grant
2024
- 2024-09-30 NO NO2024042C patent/NO2024042I1/no unknown
- 2024-10-01 FI FIC20240032C patent/FIC20240032I1/fi unknown
- 2024-10-01 HU HUS2400034C patent/HUS2400034I1/hu unknown
- 2024-10-01 LT LTPA2024526C patent/LTPA2024526I1/lt unknown
- 2024-10-01 FR FR24C1036C patent/FR24C1036I2/fr active Active
- 2024-10-02 CY CY2024027C patent/CY2024027I1/el unknown
- 2024-10-07 NL NL301292C patent/NL301292I2/nl unknown

Also Published As

Publication number	Publication date
IL243540A0 (en)	2016-02-29
IL243540B (en)	2019-09-26
WO2015009616A1 (en)	2015-01-22
PH12016500072A1 (en)	2016-04-18
CN105579444A (zh)	2016-05-11
CY2024027I2 (el)	2025-09-26
PL3022192T3 (pl)	2018-03-30
UY35663A (es)	2015-02-27
SG11201600086PA (en)	2016-02-26
SI3022192T1 (en)	2018-01-31
US9682968B2 (en)	2017-06-20
EP3299365A1 (en)	2018-03-28
BR112016000909A8 (pt)	2020-01-07
US20160152605A1 (en)	2016-06-02
HRP20172000T1 (hr)	2018-02-09
TW201546058A (zh)	2015-12-16
EA031030B1 (ru)	2018-11-30
KR20160030556A (ko)	2016-03-18
AP2016008992A0 (en)	2016-01-31
FR24C1036I2 (fr)	2025-08-01
CU20160006A7 (es)	2016-08-31
SV2016005137A (es)	2018-06-12
NZ715780A (en)	2021-03-26
BR112016000909A2 (pt)	2017-07-25
TN2016000017A1 (en)	2017-07-05
FR24C1036I1 (fr)	2024-12-06
US20180009795A1 (en)	2018-01-11
MX351291B (es)	2017-10-09
ES2655855T4 (es)	2024-09-06
CU24397B1 (es)	2019-04-04
EP3022192B1 (en)	2017-10-11
CN105579444B (zh)	2018-05-01
US10093663B2 (en)	2018-10-09
UA117371C2 (uk)	2018-07-25
NO2024042I1 (no)	2024-09-30
HUE037510T2 (hu)	2018-09-28
CL2016000060A1 (es)	2016-06-10
JO3425B1 (ar)	2019-10-20
MY196427A (en)	2023-04-10
EA201690223A1 (ru)	2016-06-30
IL268623A (en)	2019-10-31
DK3022192T3 (en)	2018-01-22
FIC20240032I1 (fi)	2024-10-01
MY187454A (en)	2021-09-22
PE20161066A1 (es)	2016-10-30
CA2917839A1 (en)	2015-01-22
RS56721B1 (sr)	2018-03-30
LT3022192T (lt)	2017-12-27
AU2014290298B2 (en)	2017-06-15
EP3022192A1 (en)	2016-05-25
GT201600007A (es)	2018-12-18
LTPA2024526I1 (nl)	2024-10-10
AU2014290298A1 (en)	2016-02-11
JP6378761B2 (ja)	2018-08-22
PH12016500072B1 (en)	2016-04-18
ES2655855T3 (es)	2018-02-21
BR112016000909B1 (pt)	2023-05-02
CY2024027I1 (el)	2025-09-26
JP2016526576A (ja)	2016-09-05
HK1221217A1 (en)	2017-05-26
KR102242742B1 (ko)	2021-04-23
CY1119767T1 (el)	2018-06-27
TWI641600B (zh)	2018-11-21
IL268623B (en)	2020-01-30
HUS2400034I1 (hu)	2024-10-28
PT3022192T (pt)	2018-01-15
CA2917839C (en)	2022-05-03

Publication	Publication Date	Title
NL301292I2 (nl)	2024-10-30	Iptacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301253I2 (nl)	2024-01-10	mavacamten of een farmaceutisch aanvaardbaar zout daarvan
NL301276I2 (nl)	2024-06-24	omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan
NL301131I2 (nl)	2021-10-25	pemigatinib of een farmaceutisch aanvaardbaar zout daarvan
NO2022005I1 (no)	2022-02-03	Zanubrutinib or a pharmaceutically acceptable salt thereof
NL301344I2 (nl)	2025-11-10	lnavolisib of een farmaceutisch aanvaardbaar zout daarvan
NO2024001I1 (no)	2024-01-09	Ritlecitinib, or a pharmaceutically acceptable salt thereof
NL301128I2 (nl)	2021-10-25	Risdiplam of een farmaceutisch aanvaardbaar zout daarvan
NL301111I2 (nl)	2021-09-27	Entrectinib of een farmaceutisch aanvaardbaar zout daarvan
NL301208I2 (nl)	2025-03-20	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NO2022004I1 (no)	2022-02-01	abrocitinib, or a pharmaceutically acceptable salt thereof
NL301286I2 (nl)	2024-09-18	Danicopan, of een farmaceutisch aanvaardbaar zout ervan
NL301254I2 (nl)	2024-01-10	Futibatinib of een zout daarvan
NL301341I2 (nl)	2025-10-02	eplontersen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
NL301201I2 (nl)	2022-12-07	Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride
NL301101I2 (nl)	2021-05-12	Latanoprost of een farmaceutisch aanvaardbaar zout daarvan en netarsudilmesylaat
NL301119I2 (nl)	2021-09-15	Selinexor of een farmaceutisch aanvaardbaar zout ervan
NL301327I2 (nl)	2025-07-17	Belzutifan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder belzutifan
FIC20230028I1 (fi)	2023-08-28	Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola
NO2022010I1 (no)	2022-04-07	ripretinib, or a pharmaceutically acceptable salt thereof
NL301149I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301154I2 (nl)	2022-07-18	Mometason of een zout daarvan en olopatadine of een zout daarvan
NL301094I2 (nl)	2021-03-18	Avapritinib en farmaceutisch aanvaardbare zouten daarvan
NL301061I2 (nl)	2020-10-08	givosiran of een farmaceutisch aanvaardbaar zout daarvan